| タイトル（別表記） | Epidemiological characteristics of novel coronavirus infection in Okayama Prefecture |
|---|---|
| フルテキストURL | 133_43.pdf |
| 著者 | 東恩納 司| 千堂 年昭| 草野 展周| 塚原 宏一| |
| キーワード | 疫学的調査 (epidemiological characteristics) 岡山 (Okayama Prefecture) 新型コロナウイルス感染症 (COVID-19) PCR検査 (PCR testing) SARS-CoV-2 |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2021-04-01 |
| 巻 | 133巻 |
| 号 | 1号 |
| 開始ページ | 43 |
| 終了ページ | 48 |
| ISSN | 0030-1558 |
| 関連URL | isVersionOf https://doi.org/10.4044/joma.133.43 |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2021 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.133.43 |
| NAID | 130008034824 |
| タイトル（別表記） | Drug interaction (50. Drug interaction mediated transporters) |
|---|---|
| フルテキストURL | 133_68.pdf |
| 著者 | 真鍋 洋平| 江角 悟| 千堂 年昭| |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2021-04-01 |
| 巻 | 133巻 |
| 号 | 1号 |
| 開始ページ | 68 |
| 終了ページ | 72 |
| ISSN | 0030-1558 |
| 関連URL | isVersionOf https://doi.org/10.4044/joma.133.68 |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2021 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.133.68 |
| NAID | 130008034821 |
| JaLCDOI | 10.18926/AMO/63410 |
|---|---|
| フルテキストURL | 76_2_167.pdf |
| 著者 | Higashionna, Tsukasa| Ushio, Soichiro| Esumi, Satoru| Murakawa, Kiminaka| Kitamura, Yoshihisa| Sendo, Toshiaki| |
| 抄録 | Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN. |
| キーワード | febrile neutropenia cefozopran cefepime lung cancer retrospective |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-04 |
| 巻 | 76巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 167 |
| 終了ページ | 172 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 35503444 |
| Web of Science KeyUT | 000792374900008 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Ushio, Soichiro| Wada, Yudai| Nakamura, Mizuki| Matsumoto, Daiki| Hoshika, Kota| Shiromizu, Shoya| Iwata, Naohiro| Esumi, Satoru| Kajizono, Makoto| Kitamura, Yoshihisa| Sendo, Toshiaki| |
| キーワード | anxiolytic inflammation immunomodulation macrophages Kampo medicine |
| 発行日 | 2022-08-12 |
| 出版物タイトル | Frontiers In Pharmacology |
| 巻 | 13巻 |
| 出版者 | Frontiers Media S.A. |
| 開始ページ | 890048 |
| ISSN | 1663-9812 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2022 Ushio, Wada, Nakamura, Matsumoto, Hoshika, Shiromizu, Iwata, Esumi, Kajizono, Kitamura and Sendo. |
| 論文のバージョン | publisher |
| PubMed ID | 36034871 |
| DOI | 10.3389/fphar.2022.890048 |
| Web of Science KeyUT | 000860773600001 |
| 関連URL | isVersionOf https://doi.org/10.3389/fphar.2022.890048 |